Polymer: Bioceramic composites optimization by tetracycline addition

International Journal of Pharmaceutics

Volumn 336, Issue 1, 2007, Pages 75-81

  Pataro, André L ^a   Oliveira, Michele F ^b   Teixeira, Karina I R ^a   Turchetti Maia, Regina M M ^b   Lopes, Miriam T P ^b   Wykrota, Francisco H L ^c   Sinisterra, Rubén D ^b   Cortés, Maria E ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b UFMG   (Brazil)

^c Hospital São Bento Cardioclínica S A   (Brazil)

Author keywords

Bioceramic; Biocompatibility; Composite; Polymer; Tetracycline

Indexed keywords

BIOCERAMICS; OSTEOSYNT; POLYGLACTIN; POLYLACTIC ACID; TETRACYCLINE; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BIOCOMPATIBILITY; CONTROLLED STUDY; CYTOTOXICITY; INFLAMMATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TISSUE REACTION; WOUND HEALING;

ANIMALS; BONE SUBSTITUTES; CALCIUM PHOSPHATES; CELL ADHESION; CELL LINE; CELL SURVIVAL; CERAMICS; DURAPATITE; FIBROBLASTS; IMPLANTS, EXPERIMENTAL; INFLAMMATION; LACTIC ACID; MALE; MATERIALS TESTING; MICE; MICROSCOPY, ELECTRON, SCANNING; POLYGLYCOLIC ACID; POLYMERS; POROSITY; SUBCUTANEOUS TISSUE; SURFACE PROPERTIES; TETRACYCLINE;

EID: 34047248050     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2006.11.038     Document Type: Article

References (42)

1. Abrams L., and Bajpai P.K. Hydroxyapatite ceramics for continuous delivery of heparin. Biomed. Sci. Instrum. 30 (1994) 169-174
2. Amin A.R., Patel R.N., Thakker G.D., Lowenstein C.J., Attur M.G., and Abramson S.B. Post-transcriptional regulation of inducible nitric oxide synthase mRNA in murine macrophages by doxycycline and chemically modified tetracyclines. FEBS Lett. 410 (1997) 259-264
3. Athanasiou K.A., Niederauer G.G., and Agrawal G.M. Sterilization, toxicity, biocompatibility and clinical applications of polylactic acid/polyglycolic acid copolymers. Biomaterials 17 (1996) 93-102
4. Bajpai P.K. Ceramics: a novel device for sustained long-term delivery of drugs. In: Hulbert J.E., and Hulbert S.F. (Eds). Bioceramics 3 (1992), Hulmam Institute of Technology, Terre Haute 87-99
5. Brundula V., Rewcastle N.B., Metz L.M., Bernard C.C., and Yong V.W. Targeting leukocyte MMPs and transmigration: minocycline as a potential therapy for multiple sclerosis. Brain 125 (2002) 1297-1308
6. Burg K.J.L., Porter S., and Kellam J.F. Biomaterial developments for bone tissue engineering. Biomaterials 21 (2000) 2347-2359
7. Chtarto A., Tenenbaum L., Velu T., Brotchi J., Levivier M., and Blum D. Minocycline-induced activation of tetracycline-responsive promoter. Neurosci. Lett. 352 (2003) 155-158
8. El Attar T.M., Lin H.S., and Shultz R. Effect of minocycline on prostaglandin formation in gingival fibroblasts. J. Periodontal. Res. 23 (1998) 285-286
9. Enduro Inc., 1991. Processo de obtenção de material biocerâmico e implante de complexo morfogenético ósseo. PI BR 9104220-8.
10. Esposito E., Cervellati C.F., Menegatti E., and Nastruzzi C. Biodegradable microparticles for sustained delivery of tetracycline to the periodontal pocket: formulatory and drug release studies. J. Microencapsulation 14 (1997) 175-187
11. Esterly N.B., Furey N.L., and Flanagan L.E. The effect of antimicrobial agents on leukocyte chemotaxis. J. Invest. Dermatol. 70 (1978) 51-55
12. Goodson J.M. Pharmacokinetic principles controlling efficacy of oral therapy. J. Dent. Res. 68 (1989) 1625-1632 (Special issue)
13. Hench L.L. Biomaterials: a forecast for the future. Biomaterials 19 (1998) 1419-1423
14. Hollinger J.O., and Battistone G.C. Biodegradable bone repair materials. Synthetic polymers and ceramics. Clin. Orthop. Rel. Re. 207 (1986) 290-305
15. Ignjatovic N., Ninkov P., Ajdukovic Z., Vasiljevic-Radovic D., and Uskokovic D. Biphasic calcium phosphate coated with poly-d,l-lactide-co-glycolide biomaterial as a bone substitute. J. Eur. Ceram. Soc. 27 (2007) 61-66
16. Ignjatovic N., and Uskokovic D. Synthesis and application of hydroxyapatite/polylactide composite biomaterial. Appl. Surf. Sci. 238 (2004) 314-319
17. ISO 10993-5, International Standards Organization, 1999. Biological evaluation for medical devices. Part 5. Tests for in vitro cytotoxicity. Geneva, 1999.
18. Kalish R.S., and Koujak S. Minocycline inhibits antigen processing for presentation to human T cells: additive inhibition with chloroquine at therapeutic concentrations. Clin. Immunol. 113 (2004) 270-277
19. Kloppenburg M., Breedveld F.C., Terwiel J., Mallee C., and Dijkmans B.A.C. Minocycline in active rheumatoid arthritis: a double blind, placebo-controlled trial. Arthritis Rheum. 37 (1994) 629-636
20. Lin F.H., Yao C.-H., Sun J.-S., Liu H.-C., and Huang C.-W. Biological effects and cytotoxicity of the composite composed by tricalcium phosphate and glutaraldehyde cross-linked gelatin. Biomaterials 19 (1998) 905-917
21. Lobo, S.H., 2002. Avaliação histomorfométrica da regeneração do tecido ósseo utilizando-se biocerâmica de hidroxiapatita e beta-tricálcio fosfato associada ou não ao concentrado de plaquetas: estudo em coelhos New Zealand. 172f. Dissertação (Mestrado em Biologia Celular), Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte.
22. Martin R.R., Warr G.A., Couch R.B., Yeager H., and Knight V. Effects of tetracyclines on leukotaxis. J. Infect. Dis. 129 (1974) 110-116
23. Nasr H.F., Aichelmann-Reidy M.E., and Yukna R.A. Bone and bone substitutes. Periodontology 19 (2000) 74-86
24. Pataro A.L., Franco C.F., Santos V.R., Cortés M.E., and Sinisterra R.D. Surface effects and desorption of tetracycline supramolecular complex on bovine dentine. Biomaterials 24 (2003) 1075-1080
25. Popovic N., Schubart A., Goetz B.D., Zhang S.-C., Linington C., and Duncan I.D. Inhibition of autoimmune encephalomyelitis by a tetracycline. Ann. Neurol. 51 (2002) 215-223
26. Pruzanski W., Greenwald R.A., Street I.P., et al. Inhibition of enzymatic activity of phospholipases A2 by minocycline and doxycycline. Biochem. Pharmacol. 44 (1992) 1165-1170
27. Ripamonti U. Smart biomaterials with intrinsic osteoinductivity: geometric control of bone differentiation. In: Davies J.E. (Ed). Bone Engineering. first ed. (1999), Rainbow Graphics and Printing Ltd., Toronto 215-222
28. Ripamonti U., Crooks J., and Kikbride A.N. Sintered porous hydroxyapatites with intrinsec osteoinductive activity: geometric induction of bone formation. S. Afric. J. Sci. 95 (1999) 335-343
29. Ritchlin C.T., Haas-Smith S.A., and Schwarz E.M. Minocycline but not doxycycline upregulates IL-10 production in human synoviocytes, mononuclear cells and synovial explants. Arthritis Rheum. 43 (2000) S345
30. Rodrigues C.V.M., Serricella P., Linhares A.B.R., Guerdes R.M., Borojevi R., Rossi M.A., Duarte M.E.L., and Farina M. Characterization of a bovine collagen-hydroxyapatite composite scaffold for bone tissue engineering. Biomaterials 24 (2003) 4987-4997
31. Ryan M.E., Greenwald R.A., and Golub L.M. Potential of tetracycline to modify cartilage breakdown in osteoarthritis. Curr. Opin. Rheumatol. 8 (1996) 238-247
32. Sapadin A.N., and Fleischmajer R. Tetracyclines: nonantibiotic properties and their clinical implications. J. Am. Acad. Dermatol. 54 (2006) 258-265
33. Scarabelli T.M., Stephanou A., Pasini E., Gitti G., Townsend P., Lawrence K., Chen-Scarabelli C., Saravolatz L., Latchman D., Knight R., and Gardin J. Preclinical investigation: minocycline inhibits caspase activation and reactivation, increases the ratio of XIAP to smac/Diablo, and reduces the mitochondrial leakage of cytochrome C and smac/Diablo. JACC 43 (2004) 865-874
34. Seymour R.A., and Heasman P.A. Tetracyclines in the management of periodontal disease. J. Clin. Periodontol. 22 (1995) 22-35
35. Shikinami Y., and Okuno M. Bioresorbable devices made of forged composites of hydroxyapatite (HA) particles and poly-l-lactide (PLLA). Part I. Basic characteristics. Biomaterials 20 (1999) 859-877
36. Sinisterra, R.D., Wykrota, F.H.L., Cortés, M.E., Oliveira, M., Pataro, A.L., Lopes, M.T.P, Regina, M.M., Turchetti-Maia, R.M.M., 2006. Processo de preparação de compósitos em base de biocerâmicas e polímeros biodegradáveis, contendo antibióticos e angiotensina (1-7), encapsulados ou não, micro ou nanoparticulados, para restituição tecidual e produtos derivados. PI 18/05/2006 N 014060005150, 18 May.
37. Thong Y.H., and Ferrante A. Inhibition of mitogen-induced human lymphocyte proliferative responses to tetracycline analogues. Clin. Exp. Immunol. 35 (1979) 443-446
38. US Pharmacopeia XXIII, 1995. US Pharmacopeial Convention. Rockville, MD, pp. 1697-1699.
39. Vandekerckhove B.N., Quirynen M., and Van Steenberghe D. The use of tetracyclin-containing controlled-release fibers in the treatment of refractory periodontitis. J. Periodontol. 68 (1997) 353-361
40. Wikesjö M.E.U., Baker J.P., and Christersson L.A. A biochemical approach to periodontal regeneration: tetracycline treatment conditions dentine surfaces. J. Periodont. Res. 21 (1986) 322-329
41. Wong W.H., and Mooney D.J. Synthesis and properties of biodegradable polymers used as synthetic matrices for tissue engineering. In: Atala A., Mooney D., Vacanti J.V., and Langer R. (Eds). Synthetic Biodegradable Polymer Scaffods. first ed. (1997), Birkhäuser, Boston 51-82
42. Wykrota L.L., Wykrota F.H.L., and Garrido C.A. Long-term bone regeneration in large human defects using calcium-phosphate particulate. In: Davies J.E. (Ed). Bone Engineering. first ed. (1999), Rainbow Graphic and Printing Ltd., Toronto 516-525